科创创新药ETF国泰（589720）涨超2%，10日吸金近5亿元

Group 1 - The core viewpoint of the news highlights a rebound in innovative pharmaceuticals, with the Guotai Innovation Drug ETF (589720) rising over 2% and attracting nearly 500 million yuan in funds over the past 10 days, currently leading its peers with a total size exceeding 1.5 billion yuan [1] - Recent industry dynamics focus on multinational collaborations and domestic innovations, exemplified by the strategic partnership between Innovent Biologics and Eli Lilly to advance global R&D in oncology and immunology, with Innovent receiving an upfront payment of 350 million USD and potential milestone payments of up to 8.5 billion USD [1] - Additionally, Carl Zeiss announced the launch of its Greater China headquarters project in Shanghai, aimed at integrating and upgrading its core functions in management, R&D, and production to strengthen its innovation network in China [1] Group 2 - Bohai Securities noted that at the 2026 JPM Healthcare Conference, numerous Chinese pharmaceutical companies showcased their latest research achievements, and there has been a surge in large-scale business development (BD) activities, indicating active collaboration with multinational corporations (MNCs) [2] - The report suggests monitoring companies that may experience a bottoming out of performance as earnings forecasts are disclosed, while also highlighting the rapid development of brain-computer interfaces and AI applications, which are expected to benefit consumer-oriented companies amid domestic demand recovery [2] - The industry faces several risks, including geopolitical tensions, product development failures, expanded centralized procurement leading to price pressures, intense competition causing price declines, and significant increases in raw material costs [2]